Embedded Files
Microorganisms have long served as nature’s chemists, producing structurally diverse metabolites that underpin many of today’s essential medicines. At Linker Sciences, we extend this foundation by combining synthetic biology, genome mining, and metabolic engineering to go beyond nature’s catalog and generate entirely new molecular entities.
Our Biologically Derived Libraries (BDL) leverages engineered bacteria, fungi, and actinomycetes to produce novel secondary metabolites with targeted pharmacological properties. By integrating pathway engineering with scalable fermentation, the platform discovers molecular scaffolds that remain inaccessible through conventional extraction or chemical synthesis.
BDLs expand the reservoir of chemical diversity for drug discovery and enable rapid progression from hit identification to lead optimization. Integrated within the Spectral Decoding Platform, the BDL technology opens access to an IP-rich chemical space and creates a high barrier to entry to positioning itself as a transformative engine for next-generation therapeutics.
Key Features:
Enables Target Customizability
Tailors biosynthetic pathways toward specific biological targets or classes for precision screening of relevant lead compounds.
Provides Novel Microbial Innovation
Leverages engineered bacteria, fungi, and actinomycetes to generate structurally diverse secondary metabolites.
Integrates Synthetic Biology
Applies genome mining, pathway engineering, and metabolic rewiring to expand beyond nature’s catalog.
Delivers Unique Chemical Space
Accesses scaffolds unattainable by conventional extraction or synthetic chemistry.
Supports Scalable Production
Employs fermentation-based processes for reliable and industrial-scale compound generation.
Establishes a High-IP Platform
Offers a disease-agnostic, defensible, high-barrier-to-entry framework with strong IP potential.
Report abuse